Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Arava Adds Physical Function Claim, Bolded Liver Safety Warning

Executive Summary

Arava labeling has been updated to include more explicit liver function monitoring directions

You may also be interested in...



FDA Looked To Arava’s Safety Experience In Gauging Aubagio’s Risks

Agency’s assessment of teriflunomide for multiple sclerosis incorporated the known safety data for leflunomide, a chemically related drug with an extensive post-marketing record in rheumatoid arthritis. Despite hepatotoxicity and other safety concerns with the older drug, its clinical experience provided reassurance that Aubagio’s risks could be managed without a REMS.

FDA Upgrades Warnings On Four Of Seven Drugs Flagged In Vioxx Testimony

An upgrade to Abbott's Meridia riskmanagement program means FDA has taken action to strengthen warnings on four of seven drugs flagged by FDA Office of Drug Safety Associate Director David Graham, MD, during the Senate Finance Committee's hearing on Vioxx

FDA Upgrades Warnings On Four Of Seven Drugs Flagged In Vioxx Testimony

An upgrade to Abbott's Meridia riskmanagement program means FDA has taken action to strengthen warnings on four of seven drugs flagged by FDA Office of Drug Safety Associate Director David Graham, MD, during the Senate Finance Committee's hearing on Vioxx

Related Content

UsernamePublicRestriction

Register

PS041988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel